Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Robinson, Stephen [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
 Caballero, D. [VerfasserIn]   i
 Corradini, P. [VerfasserIn]   i
 Geisler, C. [VerfasserIn]   i
 Ghielmini, M. [VerfasserIn]   i
 Le Gouill, S. [VerfasserIn]   i
 Kimby, E. [VerfasserIn]   i
 Rule, S. [VerfasserIn]   i
 Vitolo, U. [VerfasserIn]   i
 Dreyling, M. [VerfasserIn]   i
 Hermine, O. [VerfasserIn]   i
Titel:The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Verf.angabe:S. Robinson, P. Dreger, D. Caballero, P. Corradini, C. Geisler, M. Ghielmini, S. Le Gouill, E. Kimby, S. Rule, U. Vitolo, M. Dreyling and O. Hermine on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
E-Jahr:2015
Jahr:[2015]
Jahr des Originals:2014
Umfang:10 S.
Illustrationen:Diagramme
Fussnoten:Advance online publication: 29 August 2014 ; Gesehen am 02.07.2020
Titel Quelle:Enthalten in: Leukemia
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2015
Band/Heft Quelle:29(2015), 2, Seite 464-473
ISSN Quelle:1476-5551
Abstract:The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in ‘low-risk’ patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.
DOI:doi:10.1038/leu.2014.223
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1038/leu.2014.223
 Volltext: https://www.nature.com/articles/leu2014223
 DOI: https://doi.org/10.1038/leu.2014.223
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1703212436
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68606881   QR-Code
zum Seitenanfang